Replies to post #171576 on Biotech Values

[jbog]

Dew

Note that NVS’ Humira-FoB program, which is using the conventional BLA pathway in the US, is not seeking US interchangeability with branded Humira. This makes it a very different business proposition from what BAX/MNTA are attempting to do with their FoB compounds.

That is understood, but I'd guess their pathway will also be many years faster.